Novel strategies for improving hematopoietic reconstruction after allogeneic hematopoietic stem cell transplantation or intensive chemotherapy

References

• Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. New England J Med. 2010;363(22):2091–2101. DOI:10.1056/NEJMoa1004383
   PubMed Web of Science ®Google Scholar
• Burnett AK. Treatment of acute myeloid leukemia: are we making progress? Hematol. 2012;2012:1–6.
   PubMedGoogle Scholar
• Diaconescu R, Flowers CR, Storer B, et al. Morbidity and mortality with nonmyeloablative compared to myeloablative conditioning before hematopoietic cell transplantation from HLA matched related donors. Blood. 2004;104(5):1550–1558. DOI:10.1182/blood-2004-03-0804
   PubMed Web of Science ®Google Scholar
• Marr KA, Carter RA, Boeckh M, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: Changes in epidemiology and risk factors. Blood. 2002;100(13):4358–4366. DOI:10.1182/blood-2002-05-1496
   PubMed Web of Science ®Google Scholar
• Junghanss C, Marr KA, Carter RA, et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: A matched control study. Biol Blood Marrow Transplant. 2002;8:512–520. DOI:10.1053/bbmt.2002.v8.pm12374456
   PubMed Web of Science ®Google Scholar
• Buckley SA, Othus M, Vainstein V, et al. Prediction of adverse events during intensive induction chemotherapy for acute myeloid leukemia or high-grade myelodysplastic syndromes. Am J Hematol. 2014;89(4):423–428. DOI:10.1002/ajh.23661
   PubMed Web of Science ®Google Scholar
• Selleslag D, Suciu S, Meloni G, et al. Low dose clofarabine in combination with a standard remission induction in patients 18-60 years with previously untreated intermediate and bad risk acute myeloid leukemia or high risk myelodysplastic syndrome: Combined phase i/ii results of the eortc/gimema aml-14a trial. Haematologica. 2016. Epud. DOI:10.3324/haematol.2016.153130
   PubMed Web of Science ®Google Scholar
• Ernst P, Bacigalupo A, Ringden O, et al. A phase 3, randomized, placebo-controlled trial of filgrastim in patients with haematological malignancies undergoing matched-related allogeneic bone marrow transplantation. Arch Drug Inf. 2008;1(3):89–96. DOI:10.1111/j.1753-5174.2008.00013.x
   PubMedGoogle Scholar
• Dekker A, Bulley S, Beyene J, et al. Meta-analysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor after autologous and allogeneic stem cell transplantation. J Clin Oncol. 2006;24(33):5207–5215. DOI:10.1200/JCO.2006.06.1663
   PubMed Web of Science ®Google Scholar
• Gurion R, Belnik-Plitman Y, Gafter-Gvili A, et al. Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia. Cochrane Database Syst Rev. 2012;(6):CD008238. DOI: 10.1002/14651858.CD008238.pub3
   Google Scholar
• Amadori S, Suciu S, Jehn U, et al. Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: Final results of aml-13, a randomized phase-3 study. Blood. 2005;106(1):27–34. DOI:10.1182/blood-2004-09-3728
   PubMed Web of Science ®Google Scholar
• Baron F, Ruggeri A, Nagler A. Methods of ex vivo expansion of human cord blood cells: Challenges, successes and clinical implications. Expert Rev Hematol. 2016;9(3):297–314. DOI: 10.1586/17474086.2016.1128321
   PubMed Web of Science ®Google Scholar
• Lund TC, Boitano AE, Delaney CS, et al. Advances in umbilical cord blood manipulation-from niche to bedside. Nat Rev Clin Oncol. 2015;12(3):163–174. DOI:10.1038/nrclinonc.2014.215
   PubMed Web of Science ®Google Scholar
• Schmitt A, Tonn T, Busch DH, et al. Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation. Transfusion. 2011;51(3):591–599. DOI:10.1111/j.1537-2995.2010.02940.x
   PubMed Web of Science ®Google Scholar
• Hanley PJ, Cruz CR, Savoldo B, et al. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive t-cell populations in cord blood and will target a range of viral epitopes. Blood. 2009;114(9):1958–1967. DOI:10.1182/blood-2009-03-213256
   PubMed Web of Science ®Google Scholar
• Papadopoulou A, Gerdemann U, Katari UL, et al. Activity of broad-spectrum T cells as treatment for ADV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med. 2014;6(242):242ra283. DOI:10.1126/scitranslmed.3008825
   Web of Science ®Google Scholar
• Delaney C, Milano F, Cicconi L, et al. Infusion of a non-HLA-matched ex vivo expanded cord blood progenitor cell product after intensive acute myeloid leukaemia chemotherapy: a phase 1 trial. Lancet Haematol. 2016;3(7):e330–339. DOI:10.1016/S2352-3026(16)30023-0
   PubMed Web of Science ®Google Scholar
• Eapen M, Rocha V, Sanz G, et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: A retrospective analysis. Lancet Oncol. 2010;11(7):653–660. DOI:10.1016/S1470-2045(10)70127-3
   PubMed Web of Science ®Google Scholar
• Wagner JE, Barker JN, Defor TE, et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: Influence of cd34 cell dose and HLA disparity on treatment-related mortality and survival. Blood. 2002;100(5):1611–1618. DOI:10.1182/blood-2002-01-0294
   PubMed Web of Science ®Google Scholar
• Heimfeld S. HLA-identical stem cell transplantation: is there an optimal cd34 cell dose? Bone Marrow Transplant. 2003;31:839–845. DOI:10.1038/sj.bmt.1704019
   PubMed Web of Science ®Google Scholar
• Baron F, Baker JE, Storb R, et al. Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood. 2004;104(8):2254–2262. DOI:10.1182/blood-2004-04-1506
   PubMed Web of Science ®Google Scholar
• Baron F, Labopin M, Ruggeri A, et al. Unrelated cord blood transplantation for adult patients with acute myeloid leukemia: Higher incidence of acute graft-versus-host disease and lower survival in male patients transplanted with female unrelated cord blood-a report from Eurocord, the Acute Leukemia Working Party, and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the European group for Blood and Marrow Transplantation. J Hematol Oncol. 2015;8(1):107.
   PubMed Web of Science ®Google Scholar
• Stem Cell Trialists’ Collaborative G. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol. 2005;23(22):5074–5087. DOI:10.1200/JCO.2005.09.020
   PubMed Web of Science ®Google Scholar
• Nagler A, Labopin M, Shimoni A, et al. Mobilized peripheral blood stem cells compared with bone marrow as the stem cell source for unrelated donor allogeneic transplantation with reduced-intensity conditioning in patients with acute myeloid leukemia in complete remission: an analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2012;18(9):1422–1429. DOI:10.1016/j.bbmt.2012.02.013
   PubMed Web of Science ®Google Scholar
• Savani BN, Labopin M, Blaise D, et al. Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT. Haematologica. 2016;101(2):256–262. DOI:10.3324/haematol.2015.135699
   PubMed Web of Science ®Google Scholar
• Rocha V, Gluckman E. Improving outcomes of cord blood transplantation: HLA matching, cell dose and other graft- and transplantation-related factors. Br J Haematol. 2009;147(2):262–274. DOI:10.1111/j.1365-2141.2009.07883.x
   PubMed Web of Science ®Google Scholar
• Baron F, Little MT, Storb R. Kinetics of engraftment following allogeneic hematopoietic cell transplantation with reduced-intensity or nonmyeloablative conditioning. Blood Rev. 2005;19::153-164. DOI:10.1016/j.blre.2004.06.003
   PubMed Web of Science ®Google Scholar
• Baron F, Ruggeri A, Beohou E, et al. RIC versus MAC UCBT in adults with AML: a report from Eurocord, the ALWP and the CTIWP of the EBMT. Oncotarget. 2016. DOI:10.18632/oncotarget.9599
   Web of Science ®Google Scholar
• Finke J, Bethge WA, Schmoor C, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009;10(9):855–864. DOI:10.1016/S1470-2045(09)70225-6
   PubMed Web of Science ®Google Scholar
• Kroger N, Solano C, Wolschke C, et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. N Engl J Med. 2016;374(1):43–53. DOI:10.1056/NEJMoa1506002
   PubMed Web of Science ®Google Scholar
• Cutler C, Logan B, Nakamura R, et al. Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. Blood. 2014;124(8):1372–1377. DOI:10.1182/blood-2014-04-567164
   PubMed Web of Science ®Google Scholar
• Ringden O, Labopin M, Gorin NC, et al. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2004;22(3):416–423. DOI:10.1200/JCO.2004.06.102
   PubMed Web of Science ®Google Scholar
• Khoury HJ, Loberiza FR Jr., Ringden O, et al. Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation. Blood. 2006;107(4):1712–1716. DOI:10.1182/blood-2005-07-2661
   PubMed Web of Science ®Google Scholar
• Bishop MR, Tarantolo SR, Geller RB, et al. A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation. Blood. 2000;96:80–85.
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Smith TL, Folloder J, et al. Controlled trial of filgrastim for acceleration of neutrophil recovery after allogeneic blood stem cell transplantation from human leukocyte antigen-matched related donors. Blood. 2001;97(11):3405–3410.
   PubMed Web of Science ®Google Scholar
• Wan L, Zhang Y, Lai Y, et al. Effect of granulocyte-macrophage colony-stimulating factor on prevention and treatment of invasive fungal disease in recipients of allogeneic stem-cell transplantation: a prospective multicenter randomized phase iv trial. J Clin Oncol. 2015;33(34):3999–4006. DOI:10.1200/JCO.2014.60.5121
   PubMed Web of Science ®Google Scholar
• Naparstek E, Hardan Y, Ben-Shahar M, et al. Enhanced marrow recovery by short preincubation of marrow allografts with human recombinant interleukin-3 and granulocyte-macrophage colony-stimulating factor. Blood. 1992;80(7):1673–1678.
   PubMed Web of Science ®Google Scholar
• Nagler A, Eldor A, Naparstek E, et al. Ex vivo expansion of megakaryocyte precursors by preincubation of marrow allografts with interleukin-3 and granulocyte-macrophage colony-stimulating factor in vitro. Exp Hematol. 1995;23(12):1268–1274.
   PubMed Web of Science ®Google Scholar
• McNiece I, Jones R, Bearman SI, et al. Ex vivo expanded peripheral blood progenitor cells provide rapid neutrophil recovery after high-dose chemotherapy in patients with breast cancer. Blood. 2000;96(9):3001–3007.
   PubMed Web of Science ®Google Scholar
• Jaspers A, Baron F, Willems E, et al. Erythropoietin therapy after allogeneic hematopoietic cell transplantation: a prospective, randomized trial. Blood. 2014;124(1):33–41. DOI:10.1182/blood-2014-01-546333
   PubMed Web of Science ®Google Scholar
• Baron F, Sautois B, Baudoux E, et al. Optimization of recombinant human erythropoietin therapy after allogeneic hematopoietic stem cell transplantation. Exp Hematol. 2002;30(6):546–554.
   PubMed Web of Science ®Google Scholar
• Rubio MT, Savani BN, Labopin M, et al. Impact of conditioning intensity in t-replete haplo-identical stem cell transplantation for acute leukemia: a report from the Acute Leukemia Working Party of the EBMT. J Hematol Oncol. 2016;9(1):25. DOI:10.1186/s13045-016-0248-3
   PubMed Web of Science ®Google Scholar
• Chang YJ, Luznik L, Fuchs EJ, et al. How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation? J Hematol Oncol. 2016;9:35. DOI:10.1186/s13045-016-0265-2
   PubMed Web of Science ®Google Scholar
• Ruggeri A, Sun Y, Labopin M, et al. Post-transplant cyclophosphamide versus antithymocyte-globulin as graft versus host disease prophylaxis in haploidentical transplant. Haematologica. 2016. DOI:10.3324/haematol.2016.151779
   Web of Science ®Google Scholar
• Horwitz ME. Frassoni F, Improving the outcome of umbilical cord blood transplantation through ex vivo expansion or graft manipulation. Cytotherapy. 2015;17(6):730–738. DOI:10.1016/j.jcyt.2015.02.004
   PubMed Web of Science ®Google Scholar
• Delaney C, Heimfeld S, Brashem-Stein C, et al. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med. 2010;16(2):232–236. DOI:10.1038/nm.2080
   PubMed Web of Science ®Google Scholar
• Delaney C, Bollard CM, Shpall EJ. Cord blood graft engineering. Biol Blood Marrow Transplant. 2013;19(1 Suppl):S74–78. DOI:10.1016/j.bbmt.2012.10.015
   Google Scholar
• de Lima M, McNiece I, Robinson SN, et al. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. New England J Med. 2012;367(24):2305–2315. DOI:10.1056/NEJMoa1207285
   PubMed Web of Science ®Google Scholar
• Horwitz ME, Chao NJ, Rizzieri DA, et al. Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment. J Clin Investig. 2014;124(7):3121–3128. DOI:10.1172/JCI74556
   PubMed Web of Science ®Google Scholar
• Wagner JE Jr., Brunstein CG, Boitano AE, et al. Phase I/II trial of StemRegenin-1 expanded umbilical cord blood hematopoietic stem cells supports testing as a stand-alone graft. Cell Stem Cell. 2016;18(1):144–155. DOI:10.1016/j.stem.2015.10.004
   PubMed Web of Science ®Google Scholar
• Cutler C, Multani P, Robbins D, et al. Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation. Blood. 2013;122(17):3074–3081. DOI:10.1182/blood-2013-05-503177
   PubMed Web of Science ®Google Scholar
• Popat U, Mehta RS, Rezvani K, et al. Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood. 2015;125(19):2885–2892. DOI:10.1182/blood-2015-01-607366
   PubMed Web of Science ®Google Scholar
• van Besien K, Hari P, Zhang MJ, et al. Reduced intensity haplo plus single cord transplant compared to double cord transplant: Improved engraftment and graft-versus-host disease-free, relapse-free survival. Haematologica. 2016;101(5):634–643. DOI:10.3324/haematol.2015.138594
   PubMed Web of Science ®Google Scholar
• Barker JN, Weisdorf DJ, Wagner JE. Creation of a double chimera after the transplantation of umbilical-cord blood from two partially matched unrelated donors. New England J Med. 2001;344(24):1870–1871. DOI:10.1056/NEJM200106143442417
   PubMed Web of Science ®Google Scholar
• Barker JN, Weisdorf DJ, Defor TE, et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood. 2005;105(3):1343–1347. DOI:10.1182/blood-2004-07-2717
   PubMed Web of Science ®Google Scholar
• Stanevsky A, Shimoni A, Yerushalmi R, et al. Double umbilical cord blood transplant: More than a cell dose? Leuk Lymphoma. 2010;51(6):975–982. DOI:10.3109/10428191003699886
   PubMed Web of Science ®Google Scholar
• Haspel RL, Kao G, Yeap BY, et al. Preinfusion variables predict the predominant unit in the setting of reduced-intensity double cord blood transplantation. Bone Marrow Transplant. 2008;41(6):523–529. DOI:10.1038/sj.bmt.1705933
   PubMed Web of Science ®Google Scholar
• Ramirez P, Wagner JE, DeFor TE, et al. Factors predicting single-unit predominance after double umbilical cord blood transplantation. Bone Marrow Transplant. 2012;47(6):799–803. DOI:10.1038/bmt.2011.184
   PubMed Web of Science ®Google Scholar
• Wagner JE Jr., Eapen M, Carter S, et al. One-unit versus two-unit cord-blood transplantation for hematologic cancers. N Engl J Med. 2014;371(18):1685–1694. DOI:10.1056/NEJMoa1405584
   PubMed Web of Science ®Google Scholar
• Michel G, Galambrun C, Sirvent A, et al. Single versus double-unit cord blood transplantation for children and young adults with acute leukemia or myelodysplastic syndrome. Blood. 2016;127(26):3450–3457. DOI:10.1182/blood-2016-01-694349
   PubMed Web of Science ®Google Scholar
• Scaradavou A, Brunstein CG, Eapen M, et al. Double unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemia. Blood. 2013;121(5):752–758. DOI:10.1182/blood-2012-08-449108
   PubMed Web of Science ®Google Scholar
• Ruggeri A, Sanz G, Bittencourt H, et al. Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the acute leukemia working party of EBMT. Leukemia. 2014;28(4):779–786. DOI:10.1038/leu.2013.259
   PubMed Web of Science ®Google Scholar
• Baron F, Ruggeri A, Beohou E, et al. Comparison of outcomes after single or double unit unrelated cord blood transplantation following reduced-intensity conditioning in adults with acute leukemia: A report from Eurocord, the acute leukemia working party and the cord blood committee of the cellular therapy & immunobiology working party of the European Society for Blood and Marrow Transplantation. Haematologica. 2016;101(s1):331.
   Google Scholar
• Lamers CH, Wijers R, van Bergen CA, et al. CD4+ T-cell alloreactivity towards mismatched HLA-class II alleles early after double umbilical cord blood transplantation (dUCBT). Blood. 2016;128(17):2165–2174. DOI:10.1182/blood-2016-06-718619
   PubMed Web of Science ®Google Scholar
• Kogler G, Nurnberger W, Fischer J, et al. Simultaneous cord blood transplantation of ex vivo expanded together with non-expanded cells for high risk leukemia. Bone Marrow Transplant. 1999;24(4):397–403. DOI:10.1038/sj.bmt.1701916
   PubMed Web of Science ®Google Scholar
• Pineault N, Abu-Khader A. Advances in umbilical cord blood stem cell expansion and clinical translation. Exp Hematol. 2015;43(7):498–513. DOI:10.1016/j.exphem.2015.04.011
   PubMed Web of Science ®Google Scholar
• Sorrentino BP. Clinical strategies for expansion of haematopoietic stem cells (review). Nat Rev Immunol. 2004;4(11):878–888. DOI:10.1038/nri1487
   PubMed Web of Science ®Google Scholar
• Dallas MH, Varnum-Finney B, Delaney C, et al. Density of the notch ligand delta1 determines generation of B and T cell precursors from hematopoietic stem cells. J Exp Med. 2005;201(9):1361–1366. DOI:10.1084/jem.20042450
   PubMed Web of Science ®Google Scholar
• Briquet A, Dubois S, Bekaert S, et al. Prolonged ex vivo culture of human bone marrow mesenchymal stem cells influences their supportive activity toward nod/scid-repopulating cells and committed progenitor cells of B lymphoid and myeloid lineages. Haematologica. 2010;95(1):47–56. DOI:10.3324/haematol.2009.008524
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase ii study. Lancet. 2008;371(9624):1579–1586. DOI:10.1016/S0140-6736(08)60690-X
   PubMed Web of Science ®Google Scholar
• Bruck F, Belle L, Lechanteur C, et al. Impact of bone marrow-derived mesenchymal stromal cells on experimental xenogeneic graft-versus-host disease. Cytotherapy. 2013;15(3):267–279. DOI:10.1016/j.jcyt.2012.09.003
   PubMed Web of Science ®Google Scholar
• Baron F, Storb R. Mesenchymal stromal cells: a new tool against graft-versus-host disease? Biolblood Marrow Transpl. 2012;18(6):822–840. DOI:10.1016/j.bbmt.2011.09.003
   PubMed Web of Science ®Google Scholar
• Robinson SN, Ng J, Niu T, et al. Superior ex vivo cord blood expansion following co-culture with bone marrow-derived mesenchymal stem cells. Bone Marrow Transplant. 2006;37(4):359–366. DOI:10.1038/sj.bmt.1705258
   PubMed Web of Science ®Google Scholar
• Peled T, Shoham H, Aschengrau D, et al. Nicotinamide, a SIRT1 inhibitor, inhibits differentiation and facilitates expansion of hematopoietic progenitor cells with enhanced bone marrow homing and engraftment. Exp Hematol. 2012;40(4):342–355. DOI:10.1016/j.exphem.2011.12.005
   PubMed Web of Science ®Google Scholar
• Boitano AE, Wang J, Romeo R, et al. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science. 2010;329(5997):1345–1348. DOI:10.1126/science.1191536
   PubMed Web of Science ®Google Scholar
• Wagner JE, Brunstein C, McKenna D, et al. Stemregenin-1 (SR1) expansion culture abrogates the engraftment barrier associated with umbilical cord blood transplantation (UCBT). Blood. 2014;124(21).
   PubMed Web of Science ®Google Scholar
• Magro E, Regidor C, Cabrera R, et al. Early hematopoietic recovery after single unit unrelated cord blood transplantation in adults supported by co-infusion of mobilized stem cells from a third party donor. Haematologica. 2006;91(5):640–648.
   PubMed Web of Science ®Google Scholar
• Frassoni F, Gualandi F, Podesta M, et al. Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. Lancet Oncol. 2008;9(9):831–839. DOI:10.1016/S1470-2045(08)70180-3
   PubMed Web of Science ®Google Scholar
• Rocha V, Labopin M, Ruggeri A, et al. Unrelated cord blood transplantation: outcomes after single-unit intrabone injection compared with double-unit intravenous injection in patients with hematological malignancies. Transplantation. 2013;95(10):1284–1291. DOI:10.1097/TP.0b013e318288ca4d
   PubMed Web of Science ®Google Scholar
• Goessling W, Allen RS, Guan X, et al. Prostaglandin E2 enhances human cord blood stem cell xenotransplants and shows long-term safety in preclinical nonhuman primate transplant models. Cell Stem Cell. 2011;8(4):445–458. DOI:10.1016/j.stem.2011.02.003
   PubMed Web of Science ®Google Scholar
• Hoggatt J, Singh P, Sampath J, et al. Prostaglandin e2 enhances hematopoietic stem cell homing, survival, and proliferation. Blood. 2009;113(22):5444–5455. DOI:10.1182/blood-2009-01-201335
   PubMed Web of Science ®Google Scholar
• Xia L, McDaniel JM, Yago T, et al. Surface fucosylation of human cord blood cells augments binding to P-selectin and E-selectin and enhances engraftment in bone marrow. Blood. 2004;104(10):3091–3096. DOI:10.1182/blood-2004-02-0650
   PubMed Web of Science ®Google Scholar
• Lowenberg B, Suciu S, Archimbaud E, et al. Use of recombinant gm-csf during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: Final report of aml-11, a phase iii randomized study of the leukemia cooperative group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group. Blood. 1997;90(8):2952–2961.
   PubMed Web of Science ®Google Scholar
• Pabst T, Vellenga E, van Putten W, et al. Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine. Blood. 2012;119(23):5367–5373. DOI:10.1182/blood-2011-11-389841
   PubMed Web of Science ®Google Scholar
• Hershman D, Neugut AI, Jacobson JS, et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst. 2007;99(3):196–205. DOI:10.1093/jnci/djk028
   PubMedGoogle Scholar